Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Basilea Pharmaceutica AG (OTC: BPMUF).

Full DD Report for BPMUF

You must become a subscriber to view this report.


Recent News from (OTC: BPMUF)

Basilea Pharmaceutica's (BPMUF) CEO Ronald Scott on Full Year 2017 Results - Earnings Call Transcript
Basilea Pharmaceutica AG (BPMUF) Full Year 2017 Earnings Conference Call February 27, 2018 10:00 A.M. ET Executives Ronald Scott - Chief Executive Officer Marc Engelhardt - Chief Medical Officer David Veitch - Chief Commercial Officer and Chief Executive Officer-designate Donat...
Source: SeekingAlpha
Date: March, 01 2018 01:14
Basilea Pharmaceutica AG reports FY results
Basilea Pharmaceutica AG ( OTC:BPMUF ): FY EPS of -CHF1.79 More news on: Basilea Pharmaceutica AG, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: February, 27 2018 01:29
Week In Review: China Life Science Deals Total $550 Million
Deals and Financings Pfizer (NYSE: [[PFE]]) signed a $226 million agreement for China/Asian rights to Cresemba (isavuconazole), an antifungal drug developed by Swiss pharma Basilea (BPMUF). Previously, Pfizer acquired rights for Cresemba in Europe, Russia, Turkey and Israel. In the latest ...
Source: SeekingAlpha
Date: December, 10 2017 07:46
Basilea Pharmaceutica (BPMUF) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with this Read more ...
Source: SeekingAlpha
Date: November, 16 2017 13:37
Week In Review: Another Billion Dollar Week For China Life Science Deals
Deals and Financings Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen - possibly Alvogen's US operations - according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion. It has operations in Asia, including China, along with e...
Source: SeekingAlpha
Date: October, 01 2017 07:55
Basilea Pharmaceutica's (BPMUF) CEO Ronald Scott on Half Year 2017 Results - Earnings Call Transcript
Basilea Pharmaceutica AG ( BPMUF ) H1 2017 Earnings Conference Call August 10, 2017 10:00 AM ET Executives Ronald Scott - CEO Achim Kaufhold - CMO David Veitch - Chief Commercial Officer Donato Spota - CFO Analysts Bob Pooler - ValuationLAB Bruno Bulic - Baader-Helvea E...
Source: SeekingAlpha
Date: August, 12 2017 17:38
Basilea Pharmaceutica AG reports 1H results
Basilea Pharmaceutica AG ( OTC:BPMUF ): 1H EPS of -CHF1.90 More news on: Basilea Pharmaceutica AG, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 10 2017 03:09
3 Things In Biotech You Should Learn Today: April 23, 2017
Welcome to another edition of "3 Things in Biotech You Should Learn Today," a digest from the world of pharmaceuticals and biotechnology companies. Today we'll be giving the spotlight to some small cap stocks, one with some good news, and another with some pessimistic news. We'll also hear...
Source: SeekingAlpha
Date: April, 24 2017 00:06
Basilea Pharmaceutica (BPMUF) Presents At Db Convertible Conference
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 09 2017 17:53
Motif Bio Reduces IPO Price To Entice Investors
Quick Take UK-based Motif Bio (MTFB) has reduced the price for its IPO ADSs (American Depositary Shares). The company has reduced its price for ADSs by 32%, while increasing the number of shares it intends to sell, from 2.125 million to 2.9 million. My opinion on the IPO at the new low...
Source: SeekingAlpha
Date: November, 14 2016 17:58

 


About Basilea Pharmaceutica AG (OTC: BPMUF)

Logo for Basilea Pharmaceutica AG (OTC: BPMUF)

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non response to current treatment options.

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $665,569,109 - 03/16/2018
  • Issue and Outstanding: 9,587,570 - 10/21/2011

 


Recent Filings from (OTC: BPMUF)

Withdrawal of registration statement filed under the Securities Act
Filing Type: RWFiling Source: edgar
Filing Date: December, 09 2015
This filing is a pre-effective amendment to an F-1 filing
Filing Type: F-1/AFiling Source: edgar
Filing Date: October, 30 2015
Registration statement for certain foreign private issuers
Filing Type: F-1Filing Source: edgar
Filing Date: October, 16 2015
Filing Type: DRS/AFiling Source: edgar
Filing Date: October, 09 2015
Filing Type: DRSFiling Source: edgar
Filing Date: September, 04 2015

 

 


Daily Technical Chart for (OTC: BPMUF)

Daily Technical Chart for (OTC: BPMUF)


Stay tuned for daily updates and more on (OTC: BPMUF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BPMUF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BPMUF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of BPMUF and does not buy, sell, or trade any shares of BPMUF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/